Osseointegration of a bone-anchored limb (BAL) is an emerging rehabilitation technique that offers significant advantages over traditional socket prostheses. By addressing functional limitations and recurrent cutaneous complications, BAL systems have shown an 82%-90% increase in daily prosthesis use among patients, who also report improvements in functional ability, balance, comfort, and overall quality of life. Despite these benefits, the process of patient selection for BAL remains underdeveloped, with evidence-based guidelines still in their infancy. This article aims to propose a workflow for patient selection and screening in BAL osseointegration, leveraging the current literature, interdisciplinary clinical experience, and established models. A comprehensive evaluation process is suggested that incorporates anatomical, physiological, psychological, and lifestyle factors. These include radiological evaluation, amputation history, prosthetic component assessment, laboratory tests, psychiatric history, cognitive assessments, and considerations of home safety and postoperative care. The evaluation should ideally be conducted by an interdisciplinary team to ensure a balanced consideration of risks and benefits for each candidate. As the understanding of BAL osseointegration advances, it is expected that patient indications will expand and contraindications will be more clearly defined. The proposed workflow aims to standardize patient selection, thereby optimizing surgical outcomes and rehabilitation processes. This approach is essential for maximizing the benefits of BAL systems while ensuring patient safety and improving long-term rehabilitation outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892707 | PMC |
http://dx.doi.org/10.1097/OI9.0000000000000368 | DOI Listing |
Oncotarget
March 2025
Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue, France.
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology.
View Article and Find Full Text PDFRev Bras Enferm
March 2025
Universidade Federal de Juiz de Fora. Juiz de Fora, Minas Gerais, Brazil.
Objectives: to map the scientific production on teaching-learning strategies related to patient safety in higher education institutions across Nursing, Pharmacy, Medicine, and Dentistry programs.
Methods: this scoping review follows the Joanna Briggs Institute (JBI) guidelines and the PRISMA Extension for Scoping Reviews recommendations. The selection of studies was performed using databases, grey literature, and reverse searching, conducted by two independent and blinded reviewers.
World J Urol
March 2025
Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA.
Purpose: Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the predictive value of noninvasive tools such as PSA dynamics and MRI to determine recurrence.
Methods: We identified from our HIFU therapy prospective registry patients who developed biopsy-proven recurrence, between 2016 and 2023.
Herz
March 2025
Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Deutschland.
The recording of mortality after acute myocardial infarction can be based on different data, some of which yield very different results. These differences are due to a number of factors, including the definition of acute myocardial infarction, patient selection and the methods used to determine mortality. While routine data are primarily used for billing purposes, procedural data for coronary angiography and percutaneous coronary intervention (PCI) are used for external quality assurance and therefore only include patients who undergo invasive diagnostic procedures.
View Article and Find Full Text PDFJAMA Dermatol
March 2025
Department of Surgery, Arthur J.E. Child Comprehensive Cancer Centre, University of Calgary, Calgary, Alberta, Canada.
Importance: There is a need to identify the best performing risk prediction model for sentinel lymph node biopsy (SLNB) positivity in melanoma.
Objective: To comprehensively review the characteristics and discriminative performance of existing risk prediction models for SLNB positivity in melanoma.
Data Sources: Embase and MEDLINE were searched from inception to May 1, 2024, for English language articles.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!